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Dear Editor,
The recent manuscript analyzing whether there was a
correlation between cyclosporine levels and dyslipidemia after renal transplantation in 1391 kidney transplant
recipients (1) was read with great interest. Dyslipidemia
is a common problem after renal transplantation and a
potentially modifiable factor (2). This is particularly important because cardiovascular morbidity significantly
contributes to the below-average life expectancy found
in renal transplant patients (3).
In their cross-sectional study of 1391 subjects, Hosseini
et al. found a very high prevalence of hypercholesterolemia (58.8%) and hypertriglyceridemia (86.6%) (1). Using univariate correlation analysis, they found only a
weak correlation between cyclosporine levels two hours
post-intake (C2) and dyslipidemia (Pearson correlation
coefficient 0.18 and 0.16 for hypercholesterolemia and
hypertriglyceridemia, respectively). C2-monitoring is the
preferred method for assessing cyclosporine exposure,
although there are some challenges with timely C2 blood
sampling, and some patients may suffer toxicity or rejection when switching from trough level (C0) to C2 monitoring (4). Using logistic multivariate regression, only serum
creatinine was associated with hyperlipidemia. Hosseini’s
study did not assess the correlation of steroid levels or
the steroid dose and dyslipidemia, even though steroid
therapy is a well-known risk factor for hyperlipidemia and
steroid avoidance has been a powerful tool to reduce the
prevalence of hyperlipidemia in liver transplantation (5).
Hosseini’s study has several other limitations. No validation of the fasting state occurred. The results of the logistic regression were not well documented, and it is unclear
what factors were included in the multivariate analysis.
The limitations of the cross-sectional retrospective study
are not well discussed, and such a study can only assess an
association, no causality. Nonetheless, the stronger correlation of the hypertriglyceridemia with the GFR (measured as serum creatinine) is interesting; it is disappoint-

ing that targeting optimal calcineurin inhibitor exposure
has little effect on hyperlipidemia. The authors call for
prospective trials targeting better lipid control, with the
hope that long-term outcomes will improve.
The authors are correct in their assessment that chronic
kidney disease (CKD)-related complications after renal
transplantation are poorly managed (3, 6, 7). Often, there
is undertreatment of dyslipidemia. Longevity after renal
transplantation could be improved significantly if similar multidisciplinary clinics were introduced as for CKD
in the primary kidneys (8). It is of the utmost importance
to determine whether targeting conventional cardiovascular risk factors can effectively modify cardiovascular
morbidity (9). In a large study of national data, Sciarretta
et al. found no association of renal damage with cardiovascular disease and the individual cardiovascular risk
profile (9). It is also important to determine which intervention is most effective and what novel therapies can
be employed to lower triglycerides. There is no known
effective treatment of hypertriglyceridemia. Dietary approaches such as supplementation with omega-3 fatty
acids should be studied prospectively (10).
Nonetheless, the undersigned is delighted that the attention is shifting towards modifiable long-term complications after renal transplantation. Cardiovascular risk
factors are among the most significant factors affecting
long-term outcomes in renal transplant recipients and
are responsible for deaths with functioning graft. CKD is
a major risk factor for cardiovascular morbidity following transplantation, and has a high prevalence in both
renal and non-renal transplant patients. The relationship between impaired GFR and dyslipidemia needs to be
studied further and effective therapeutic interventions
have to be found.

Financial Disclosure

There are no conflicts of interest or financial disclosures
to be discussed.

Copyright © 2014, Nephrology and Urology Research Center; Published by Kowsar Corp. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Filler G

References
1.

2.

3.

4.

5.

2

Hosseini M, Rostami Z, Einollahi B. Dyslipidemia After Kidney
Transplantation and Correlation With Cyclosporine Level. Nephr
Urol Mon. 2013;5(3):831–4.
Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske
BL, et al. Controlling the epidemic of cardiovascular disease
in chronic renal disease: what do we know? What do we need
to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Ame J Kidney Dis.
1998;32(5):853–906.
Filler G. Challenges in pediatric transplantation: the impact of
chronic kidney disease and cardiovascular risk factors on longterm outcomes and recommended management strategies. Pediatr Transplant. 2011;15(1):25–31.
Zhang Y, Zhang XD, Wang Y. Efficacy and safety of changing from
cyclosporine C0 to C2 monitoring in stable recipients following
renal transplantation: a prospective cohort study. Transplant
Proc. 2011;43(10):3697–701.
Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath
PJ, et al. Steroid avoidance in liver transplantation: meta-anal-

6.
7.

8.
9.

10.

ysis and meta-regression of randomized trials. Liver Transpl.
2008;14(4):512–25.
Feber J, Wong H, Geier P, Chaudry B, Filler G. Complications of
chronic kidney disease in children post-renal transplantation - a
single center experience. Pediatr Transplant. 2008;12(1):80–4.
Akbari A, Hussain N, Karpinski J, Knoll GA. Chronic kidney disease management: comparison between renal transplant recipients and nontransplant patients with chronic kidney disease.
Nephron Clin Pract. 2007;107(1):c7–13.
Filler G, Lipshultz SE. Why multidisciplinary clinics should be
the standard for treating chronic kidney disease. Pediatr Nephrol.
2012;27(10):1831–4.
Sciarretta S, Valenti V, Tocci G, Pontremoli R, Rosei EA, Ambrosioni E, et al. Association of renal damage with cardiovascular
diseases is independent of individual cardiovascular risk profile
in hypertension: data from the Italy - Developing Education and
awareness on MicroAlbuminuria in patients with hypertensive
Disease study. J Hypertens. 2010;28(2):251–8.
Filler G, Weiglein G, Gharib MT, Casier S. Omega3 fatty acids may
reduce hyperlipidemia in pediatric renal transplant recipients.
Pediatr Transplant. 2012;16(8):835–9.

Nephro Urol Mon. 2014;6(1):e14296

